Cancer Incidence and Mortality in a Cohort of US Blood Donors: A 20-Year Study
Table 4
Adjusted Cox proportional regression models for all-cause mortality, comparing donors and nondonors with cancer, by cancer site, Blood Centers of the Pacific and California Cancer Registry, 1991–2009 ( = 24,927).
Donors
Nondonors
Adjusted HR*
-value
(%)
Mortality (%)
(%)
Mortality (%)
All cancer sites**
4,805
(100)
27.1
20,122
(100)
45.0
0.70
<0.001
Followup < 5 years
2,519
(52.4)
42.0
11,319
(56.3)
59.1
0.75
<0.001
Followup 5 years
2,286
(47.6)
10.6
8,803
(43.7)
27.0
0.65
<0.001
By cancer site
Oral cavity and pharynx
80
(1.7)
40.0
322
(1.6)
52.8
0.66
0.05
Digestive
559
(11.6)
48.1
2,395
(11.9)
68.9
0.70
<0.001
Respiratory
348
(7.2)
83.3
1,653
(8.2)
86.6
0.93
0.25
Skin
487
(10.1)
7.6
1,628
(8.1)
18.0
0.57
<0.01
Breast
914
(19.0)
10.5
3,451
(17.2)
27.2
0.51
<0.001
Female genital
405
(8.4)
16.8
1,735
(8.6)
32.1
0.68
<0.01
Male genital
1,025
(21.3)
14.2
5,010
(24.9)
39.3
0.57
<0.001
Urinary
241
(5.0)
30.7
1,078
(5.4)
53.4
0.70
<0.01
Brain and nervous
117
(2.4)
47.9
451
(2.2)
56.3
0.68
0.01
Endocrine
114
(2.4)
3.5
409
(2.0)
11.5
0.25
<0.01
Lymphoma
219
(4.6)
28.3
822
(4.6)
47.7
0.55
<0.001
Myeloma
50
(1.0)
66.0
176
(1.0)
68.2
1.00
1.00
Leukemia
104
(2.2)
51.0
385
(1.9)
65.2
0.70
0.03
Other∧
142
(3.0)
57.0
607
(3.0)
68.4
0.98
0.89
Adjusted models include age at diagnosis, sex, race, tumor metastasis, tumor stage and grade, and SES.
**Cox models are stratified by cancer site; that is, baseline hazard is adjusted by site. ∧Other includes mesothelioma, Kaposi sarcoma, eye and orbit, bone, soft tissue, and miscellaneous (SEER site recode ICD-O-3 definition).
